tradingkey.logo

Drugs Made In America Acquisition II Ord Shs

DMII
9.990USD
+0.030+0.30%
Fechamento 02/06, 16:00ETCotações atrasadas em 15 min
655.09MValor de mercado
--P/L TTM

Drugs Made In America Acquisition II Ord Shs

9.990
+0.030+0.30%

Mais detalhes de Drugs Made In America Acquisition II Ord Shs Empresa

Drugs Made In America Acquisition II Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The Company intends to search for business combination targets in the pharmaceutical industry. The Company is neither engaged in any operations nor generated any revenues.

Informações de Drugs Made In America Acquisition II Ord Shs

Código da empresaDMII
Nome da EmpresaDrugs Made In America Acquisition II Corp
Data de listagemSep 25, 2025
CEOStockwell (Lynn)
Número de funcionários- -
Tipo de títulosOrdinary Share
Fim do ano fiscal- -
Endereço1 East Broward Boulevard
CidadeFT LAUDERDALE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal33301
Telefone19548703099
Site
Código da empresaDMII
Data de listagemSep 25, 2025
CEOStockwell (Lynn)

Executivos da empresa Drugs Made In America Acquisition II Ord Shs

Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
100.00K
+100000.00%
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
100.00K
+100000.00%
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
100.00K
+100000.00%
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Glenn Worman
Mr. Glenn Worman
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director
Independent Director
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director
Independent Director
--
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Glenn Worman
Mr. Glenn Worman
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
100.00K
+100000.00%
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
100.00K
+100000.00%
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
100.00K
+100000.00%
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Glenn Worman
Mr. Glenn Worman
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director
Independent Director
--
--

Detalhamento da receita

Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.

Distribuição de ações

Atualizado em: sáb, 7 de fev
Atualizado em: sáb, 7 de fev
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Drugs Made In America Acquisition II LLC
7.37%
Conaway (Charles C.)
3.05%
MAABS, LLC
2.03%
King (Michael)
2.03%
Wolverine Asset Management, LLC
1.62%
Outro
83.89%
Investidores
Investidores
Proporção
Drugs Made In America Acquisition II LLC
7.37%
Conaway (Charles C.)
3.05%
MAABS, LLC
2.03%
King (Michael)
2.03%
Wolverine Asset Management, LLC
1.62%
Outro
83.89%
Tipos de investidores
Investidores
Proporção
Corporation
9.40%
Individual Investor
8.23%
Investment Advisor
2.90%
Hedge Fund
1.62%
Investment Advisor/Hedge Fund
0.12%
Outro
77.72%

Participação acionária institucional

Atualizado em: qua, 21 de jan
Atualizado em: qua, 21 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q4
1
666.67K
0.00%
--
2025Q4
5
1.84M
2.81%
+1.84M

Atividade dos acionistas

Nome
Ações detidas
Proporção
Variação
Var. %
Data
Drugs Made In America Acquisition II LLC
4.83M
7.37%
+4.83M
--
Dec 03, 2025
Conaway (Charles C.)
2.00M
3.05%
+2.00M
--
Dec 03, 2025
MAABS, LLC
1.33M
2.03%
+1.33M
--
Dec 03, 2025
King (Michael)
1.33M
2.03%
+1.33M
--
Dec 03, 2025
Robinson (Edward)
1.00M
1.52%
+1.00M
--
Dec 03, 2025
Jessnick Capital Management, LLC
666.67K
1.02%
+666.67K
--
Dec 03, 2025
Higbee (Tyler)
666.67K
1.02%
+666.67K
--
Dec 03, 2025
Ver Mais

ETFs Relacionados

Nome
Proporção
Sem dados

Dividendo

Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados

Desdobramento de ações

Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
KeyAI